In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 5107-5111

  Hutschala, Doris ^a   Skhirtladze, Keso ^a   Zuckermann, Andreas ^a   Wisser, Wilfried ^a   Jaksch, Peter ^a   Mayer Helm, Bernhard Xaver ^b   Burgmann, Heinz ^a   Wolner, Ernst ^a   Müller, Markus ^b   Tschernko, Edda M ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATELECTASIS; CAPILLARY LEAK SYNDROME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LUNG LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; HEART OUTPUT; HEART SURGERY; HOSPITAL INFECTION; HUMAN; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; LUNG INTERSTITIUM; LUNG PARENCHYMA; MALE; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA;

AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG; MIDDLE AGED; OFLOXACIN; PNEUMONIA; PSEUDOMONAS INFECTIONS;

EID: 28844468813     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.5107-5111.2005     Document Type: Article

References (25)

1. Ariano, R. E., and G. G. Zhanel. 1991. Antimicrobial prophylaxis in coronary bypass surgery: a critical appraisal. Drug Intell. Clin. Pharm. 25:478-484.
2. Bellchambers, J., J. M. Harris, P. Cullinan, H. Gaya, and J. R. Pepper. 1999. A prospective study of wound infection in coronary artery surgery. Eur. J. Cardiothorac. Surg. 15:45-50.
3. Brunner, M., T. Pernerstorfer, B. X. Mayer, H. G. Eichler, and M. Müller. 2000. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit. Care Med. 28:1754-1759.
4. Capitano, B., H. M. Mattoes, E. Shore, A. O'Brien, S. Braman, C. Sutherland, and D. P. Nicolau. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin. and azithromycin in older adults. Chest 125:965-973.
5. Carrel, T., E. R. Schmid, L. von Segesser, M. Vogt, and M. Turina. 1991. Perioperative assessment of the likelihood of infeetion of the lower respiratory tract after cardiac surgery. Thorac. Cardiovasc. Surg. 39:85-88.
6. Cunha, B. A. 2001. Nosocomial pneumonia. Diagnostic and therapeutic considerations. Med. Clin. N. Am. 85:79-114.
7. FDA. Guidance for industry. Developing antimicrobial drugs. General considerations for clinical trials. [Online.] http://www.fda.gov/cdcr/guidance /2580dft.pdf.
8. Florea, N. R., P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau. 2004. Pharmacodynamics of moxifloxacin and Icvofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48:1215-1221.
9. Fogarty, C. M., J. G. Sullivan, and M. S. Chattman. 1998. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect. Dis. Clin. Pract. 7:400-407.
10. Georgopoulos, A., A. Buxbaum, U. Straschil, the Austrian Bacterial Surveillance Network, and W. Graninger. 1998. Austrian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae 1994-96. Scand. J. Infect. Dis. 30:345-349.
11. Hoogkamp-Korstanje, J. A. A. 1997. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. J. Antimicrob. Chemother. 40:427-431.
12. Joukhadar, C., H. Derenhdorf, and M. Müller. 2001. Microdialysis, a novel tool for clinical studies of anti-infective agents. Eur. J. Clin. Pharmacol. 57:211-219.
13. Klimberg, I. W., C. E. Cox, and C. L. Fowler. 1998. A controlled trial of levofloxacin and lomefloxaein in the treatment of complicated urinary tract infection. Urology 51:610-615.
14. Lönnroth, P., P. A. Jansson, and U. Smith. 1987. A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol. 253:E228-E231.
15. Magnusson, L., V. Zemgulis, S. Wicky, H. Tyden, S. Thelin, and G. Hedenstiema. 1997. Atelectasis is a major cause of hypoxemia and shunt after cardiopulmonary bypass: an experimental study. Anesthesiology 87:1153-1163.
16. Marffraff, G., F. H. Splittgerber, M. Knox, and J. C. Reidmeister. 1999. Mediastinitis after cardiac surgery-epidemiology and current treatment. Eur. J. Surg. Suppl. 584:12-16.
17. Martin, S. J., R. Jung, and C. G. Garvin. 2001. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Drug Safety 24:199-222.
18. Müller, M., O. Haag, T. Burgdorff, A. Georgopoulos, W. Wenninger, B. Jansen, G. Stanek, H. Pehamberger, E. Agneter, and H. G. Eichler. 1996. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob. Agents Chemother. 40:2703-2709.
19. Neckel, U., C. Joukhadar, M. Frossard, W. Jäger, M. Müller, and B. M. Mayer. 2000. Simultaneous determination of levofloxacin and ciprofloxacin in microdialysates and plasma by high-performance liquid chromatography. Anal. Chim. Acta 463:199-206.
20. Noel, G. J., D. B. Goodman, S. Chien, B. Solanki, and M. Padmanabhan. 2004. Measuring the effects of supratherapeutie doses of levofloxacin on healthy volunteers using four methods correction and periodic and continuous ECG recording. J. Clin. Pharmacol. 44:464-473.
21. Slaughter, M. S., M. M. Olson, J. T. Lee, and H. B. Ward. 1993. A fifteen-year wound surveillance study after coronary artery bypass. Ann. Thorac. Surg. 56:1063-1068.
22. Stahle, E., A. Tammelin, R. Bergstrom, A. Hambreus, S. O. Nystrom, and H. E. Hansson. 1997. Sternal wound complications-incidence, microbiology and risk factors. Eur. J. Cardiothorac. Surg. 11:1146-1153.
23. Wise, R., J. M. Andrews, C. Cross, and L. J. V. Piddock. 1985. The antimicrobial activity of ecfpiromc, a new cephalosporin. J. Antimicrob. Chemother. 15:449-456.
24. Zacharias, A., and R. H. Habib. 1996. Factors predisposing to median sternotomy complications. Deep vs. superficial infection. Chest 110:1173-1238.
25. Zeitlinger, M. A., P. Dehghanyar, B. X. Mayer, B. S. Schenks, U. Neckel, G. Herkner, A. Georgopoulos, M. Mueller, and C. Joukhadar. 2003. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob. Agents Chemother. 47:3548-3553.